BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Capuano C, Pighi C, Battella S, De Federicis D, Galandrini R, Palmieri G. Harnessing CD16-Mediated NK Cell Functions to Enhance Therapeutic Efficacy of Tumor-Targeting mAbs. Cancers (Basel) 2021;13:2500. [PMID: 34065399 DOI: 10.3390/cancers13102500] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Lin X, Li F, Gu Q, Wang X, Zheng Y, Li J, Guan J, Yao C, Liu X. Gold-seaurchin based immunomodulator enabling photothermal intervention and αCD16 transfection to boost NK cell adoptive immunotherapy. Acta Biomater 2022;146:406-20. [PMID: 35470078 DOI: 10.1016/j.actbio.2022.04.029] [Reference Citation Analysis]
2 Li Y, Wu L, Liu Y, Ma S, Huang B, Feng X, Wang H. A novel multifunctional anti-PD-L1-CD16a-IL15 induces potent cancer cell killing in PD-L1-positive tumour cells. Transl Oncol 2022;21:101424. [PMID: 35477065 DOI: 10.1016/j.tranon.2022.101424] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Lee EHC, Wong DCP, Ding JL. NK Cells in a Tug-of-War With Cancer: The Roles of Transcription Factors and Cytoskeleton. Front Immunol 2021;12:734551. [PMID: 34594338 DOI: 10.3389/fimmu.2021.734551] [Reference Citation Analysis]
4 Kusowska A, Kubacz M, Krawczyk M, Slusarczyk A, Winiarska M, Bobrowicz M. Molecular Aspects of Resistance to Immunotherapies-Advances in Understanding and Management of Diffuse Large B-Cell Lymphoma. Int J Mol Sci 2022;23:1501. [PMID: 35163421 DOI: 10.3390/ijms23031501] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Reusch U, Ellwanger K, Fucek I, Müller T, Schniegler-mattox U, Koch J, Tesar M. Cryopreservation of Natural Killer Cells Pre-Complexed with Innate Cell Engagers. Antibodies 2022;11:12. [DOI: 10.3390/antib11010012] [Reference Citation Analysis]
6 Omer N, Nicholls W, Ruegg B, Souza-Fonseca-Guimaraes F, Rossi GR. Enhancing Natural Killer Cell Targeting of Pediatric Sarcoma. Front Immunol 2021;12:791206. [PMID: 34804076 DOI: 10.3389/fimmu.2021.791206] [Reference Citation Analysis]
7 Lejeune M, Duray E, Peipp M, Clémenceau B, Baron F, Beguin Y, Caers J. Balancing the CD38 Expression on Effector and Target Cells in Daratumumab-Mediated NK Cell ADCC against Multiple Myeloma. Cancers (Basel) 2021;13:3072. [PMID: 34203012 DOI: 10.3390/cancers13123072] [Reference Citation Analysis]
8 Di Vito C, Calcaterra F, Coianiz N, Terzoli S, Voza A, Mikulak J, Della Bella S, Mavilio D. Natural Killer Cells in SARS-CoV-2 Infection: Pathophysiology and Therapeutic Implications. Front Immunol 2022;13:888248. [DOI: 10.3389/fimmu.2022.888248] [Reference Citation Analysis]
9 Iyer A, Hamers AAJ, Pillai AB. CyTOF® for the Masses. Front Immunol 2022;13:815828. [DOI: 10.3389/fimmu.2022.815828] [Reference Citation Analysis]
10 Tarannum M, Romee R, Shapiro RM. Innovative Strategies to Improve the Clinical Application of NK Cell-Based Immunotherapy. Front Immunol 2022;13:859177. [PMID: 35401529 DOI: 10.3389/fimmu.2022.859177] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
11 Chen RP, Shinoda K, Rampuria P, Jin F, Bartholomew T, Zhao C, Yang F, Chaparro-Riggers J. Bispecific antibodies for immune cell retargeting against cancer. Expert Opin Biol Ther 2022. [PMID: 35485219 DOI: 10.1080/14712598.2022.2072209] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Muraro E, De Zorzi M, Miolo G, Lombardi D, Scalone S, Spazzapan S, Massarut S, Perin T, Dolcetti R, Steffan A, De Re V. KIR-HLA Functional Repertoire Influences Trastuzumab Efficiency in Patients With HER2-Positive Breast Cancer. Front Immunol 2021;12:791958. [PMID: 35095867 DOI: 10.3389/fimmu.2021.791958] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]